Akeso Advances reports first patient dosed in AK146D1 combined with ivonescimab breast cancer study

BioInvent receives FDA Fast Track designation for BI-1808 in ovarian cancer

Northwest Biotherapeutics signs MOU for collaboration with SPIMACO in Saudi Arabia

Innovent doses first colorectal cancer patient with IBI363/TAK-928 in combination with bevacizumab

Citius Oncology reports growing LYMPHIR adoption and market access

Obsidian Therapeutics advances Agni-01 study with first patient enrolled in registration-enabling cohort

Summit Therapeutics expands ivonescimab programme into bladder cancer with Phase II/III trial

Lilly secures FDA Breakthrough Therapy designation for olomorasib in pancreatic cancer

Genprex collaborates with Roche Diagnostics on NSCLC biomarker validation

Zai Lab's zoci receives FDA orphan designation for neuroendocrine carcinomas

CelLBxHealth study highlights Parsortix potential in ADC biomarker monitoring

Qatar approves Zepzelca combination as first-line maintenance therapy for extensive-stage small cell lung cancer

Coiled Therapeutics doses first patient with optimised AO-252 formulation

GlycoNex commences dosing in Phase I trial of GNX1021 in Japan

IMPACT Therapeutics grants Pharmanovia exclusive rights to senaparib across 66 countries